{"filing":{"accession_number":"0001437749-26-025302","cik":"0001595248","ticker":"GNPX","company_name":"Genprex, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"gnpx20260802_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926025302/gnpx20260802_8k.htm"},"events":[{"id":23396,"run_id":21149,"accession_number":"0001437749-26-025302","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Genprex announced a strategic collaboration with Roche Diagnostics to validate biomarkers (TROP2 and PTEN) for patient selection in NSCLC clinical trials. This is a material operational and strategic partnership that advances the company's clinical development program and precision medicine approach, with anticipated completion of validation studies by end of 2026 and integration into the NSCLC clinical program thereafter. The collaboration leverages Roche's FDA Breakthrough Device Designation and represents a significant strategic alignment for accelerating patient identification and recruitment.","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23608,"accession_number":"0001437749-26-025302","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Genprex announced a strategic collaboration with Roche Diagnostics to validate biomarkers (TROP2 and PTEN) for patient selection in NSCLC clinical trials. This is a material operational and strategic partnership that advances the company's clinical development program and precision medicine approach, with anticipated completion of validation studies by end of 2026 and integration into the NSCLC clinical program thereafter. The collaboration leverages Roche's FDA Breakthrough Device Designation and represents a significant strategic alignment for accelerating patient identification and recruitment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:25:08.472404+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23608,"accession_number":"0001437749-26-025302","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Genprex announced a strategic collaboration with Roche Diagnostics to validate biomarkers (TROP2 and PTEN) for patient selection in NSCLC clinical trials. This is a material operational and strategic partnership that advances the company's clinical development program and precision medicine approach, with anticipated completion of validation studies by end of 2026 and integration into the NSCLC clinical program thereafter. The collaboration leverages Roche's FDA Breakthrough Device Designation and represents a significant strategic alignment for accelerating patient identification and recruitment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:25:08.472404+00:00","company_name":"Genprex, Inc.","ticker":"GNPX","filing_date":"2026-08-03"}]}